Seronegative APS After Immunosuppression: Guideline Resources
For information on APS in patients who become seronegative after immunosuppressive therapy, consult the 2025 ISTH-SSC guidance on antiphospholipid antibody detection 1, the 2023 ACR/EULAR APS classification criteria (referenced in multiple sources), and the 2019 EULAR recommendations for APS management 2.
Primary Guideline Resources
The most current and comprehensive guidance comes from:
2025 ISTH-SSC Guidance 1: This provides the most recent laboratory interpretation framework, specifically addressing repeat testing and the clinical significance of antibody profiles. Critically, it recommends two consecutive negative aPL tests at least 12 weeks apart to confirm true seronegativity (ruling out transient negativity), and emphasizes that the same antibodies need to be positive in repeat testing for diagnosis.
2019 EULAR Recommendations 2: These address management strategies including the role of immunomodulatory therapies (hydroxychloroquine, rituximab) that may reduce antibody levels, though they emphasize these should be adjunctive to anticoagulation rather than replacing it.
2023 ACR/EULAR Classification Criteria (referenced in 3, 4, 5): This newer weighted, domain-based scoring system provides enhanced diagnostic precision and broader recognition of APS manifestations, particularly relevant when antibody status changes.
Key Concepts for Seronegative Scenarios
Seroconversion vs. Seronegative APS
The guidelines distinguish two critical scenarios 6:
aPL Seroconversion: Transition from persistent antibody positivity to sustained negativity, confirmed by at least two negative tests ≥12 weeks apart and maintained for over one year. This occurs in patients previously meeting laboratory criteria.
Seronegative APS (SNAPS): Patients with APS-like clinical features who never fulfill standard laboratory criteria 7, 3. This is distinct from post-immunosuppression seronegativity.
Management After Immunosuppression-Induced Seronegativity
Anticoagulation should NOT be discontinued solely based on seroconversion or adjunctive immunosuppressive treatment 6. The thrombotic risk remains significant, particularly in patients with prior thrombotic events. Immunomodulatory therapies may allow cautious adjustments in low-risk patients, but decisions must be guided by:
- Clinical phenotype (thrombotic vs. obstetric)
- Prior thrombotic events
- Antibody profile before seroconversion (triple vs. single positivity)
- Duration of seronegativity
Laboratory Considerations
The 2025 ISTH guidance 1 emphasizes close laboratory-clinician interaction when interpreting results in patients on immunosuppressants, as these medications can interfere with antibody detection. The guidance specifically notes that results should be interpreted in clinical context with knowledge of concurrent therapies.
Areas Requiring Further Research
The 2025 ISTH guidance 1 explicitly identifies knowledge gaps relevant to your question:
- Value and therapeutic consequences of repeat aPL testing after treatment
- Role of non-criteria antibodies (anti-domain I, antiphosphatidylserine/prothrombin) in seronegative presentations
- Evaluation of alternative antibodies in patients negative for standard tests where APS suspicion remains high
The evidence base for managing post-immunosuppression seronegativity remains limited, with patient selection for therapy adjustments requiring individualized risk assessment rather than protocol-driven approaches 6.